1 / 10

9th EACS ADVANCED HIV/AIDS COURSE AIX-EN-PROVINCE 7-9th September

9th EACS ADVANCED HIV/AIDS COURSE AIX-EN-PROVINCE 7-9th September. Dr KANHON SERGE Conseiller technique Soin et traitement PNPEC/MSLS CAP-VERT du 14 au 16 Mars 2011. Dr KANHON SERGE, MD Care and Treatment Senior Technical Advisor NACP/ MoH. OUTLINE.

luisa
Download Presentation

9th EACS ADVANCED HIV/AIDS COURSE AIX-EN-PROVINCE 7-9th September

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 9th EACS ADVANCED HIV/AIDS COURSEAIX-EN-PROVINCE7-9th September Dr KANHON SERGE Conseiller technique Soin et traitementPNPEC/MSLSCAP-VERT du 14 au 16 Mars 2011 Dr KANHON SERGE, MD Care and Treatment Senior TechnicalAdvisor NACP/MoH

  2. OUTLINE • BACKGROUND • EPIDEMIOLOGY • RESULTS • STRATEGIES • CHALLENGES • WAY FORWARD • CONCLUSION

  3. BACKGROUND • Location: West Africa • Size: 322 462 sq km • UNDP 2006: 164/ 177 with HDI 41,5% (low) • GDP: 1 136 USD per capita • Population: 20 581 777 inhabitants in 2007 • Death rate: 14/1000 • Child death : 125/1000 • Maternaldeath: 543/ 100 000 • Birth rate - 45/1000; • Life expectancy : 51,3 yrs • Population growth 2,8% • 3 major diseases: Malaria, HIV/Aids, TB

  4. EPIDEMIOLOGY • CI most affected: prevalence 3,2% UNAIDS 2010 ( ANC: 5,6% vs 2,9%) • 1986: 1st case notification • HIV 1 and HIV 2 but dual infection • PlwHIV: 480 000 (180 000 in need of treatment) • 30 000 new infections all age • 35 000 number of death • 40% ART coverage and 50% PMTCT coverage • 39% of HIV-TB coinfection • 102 lab (4 VL) • ARV and lab testing are free of charge

  5. RESULTS

  6. STRATEGIES • PLANIFICATION • NSP: 2011-2015: • To reducefrom 30% new infections and STD on 2015 • To enrolle 80% of adults and adolecentseligible for treatment on 2015 • EXP for healthsector • TRAINNING • Health workers (265 trainnings session to train 5723) • National pool of trainners • Regional pool of trainners • Mentorship • Refreshing sessions • COORDINATION: • TB program, VHB program, MoD • National political documents for CT, PMTCT, PED treatment, TARV, laboratory management

  7. STRATEGIES (2) • INNOVATIVES APPROCHES: • PICT: • Task shiffting: NIMART (Nurse Initiated and Managed ART) pilot project • Emtct: Elimination of MTCT • The Expanded Treatment Program (Decentralized access to treatment: facilities, other than ARV clinics to initiate treatment) • New Treatment guidelines : In line with WHO recommendations, Eligibility Criteria reviewed, TDF in 1st line regimen, to reduce the use of Stavudine, PMTCT and children regimens reviewed. • PARTNERSHIP • Keys Technical Partners: WHO, UNAIDS • Financial Partners: GoCI, PEPFAR, WB, GFATM, UNICEF, UNFPA, WAHO, GIP-ESTHER, • Implementing Partners: EGPAF, FHI, ICAP, ACONDA, PSI, Alliance CI, JHPIEGO, JHU-CCP, URC, HAI, Abt Associates, … • Local partners: Network, NGO, Private Sector…

  8. CHALLENGES • COUNSELLING AND TESTING • available at all health facilities (public, private, community based) • PMTCT AND PEDIATRIC CARE • eMTCT • EID • CARE AND TREATMENT FOR ADULT • To reduce LTFU • Low coverage of ART despite increased sites • LOGISTIC • Commodity stock-outs • Donor driven procurement of commodities • FUNDING • Sustainbility • HIS • Weak health information management systems, • Identifying trends & Using Data Sets for secondary analysis • Need to develop M&E systems that meet multiple needs

  9. WAY FORWARD • Primary Prevention • Advocacy and sensitization • Continue to build systems for improved access and capacity strengthening • Competing for additionnal funding • Maintain the highest level of good business practice and high quality care and treatment • Continue to receive technical assistance from donor agencies • Involvement of other stakeholders including FBOs and private health care providers • Effective monitoring and evaluation • Health system strengthening (logistics and supplies) • Political commitment: Governance and leadership, value for money

  10. CONCLUSION • Significant results were obtained for ART treatment in PLWHIV • However, to maintain this positive dynamic , it remains critical to overcome some keys challenges • Funding sustainability • Avoid stock out (ARV) • Minimize LTFU • Implement WHO new recommendations

More Related